United Therapeutics (UTHR) Misses Q4 EPS by $2.05, Misses on Revenue
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $547.06 -0.98%
Revenue Growth %: +1.1%
Financial Fact:
Other, net: 1M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +1.1%
Financial Fact:
Other, net: 1M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $519.21 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- United Therapeutics Corp. (UTHR) PT Lowered to $714 at Jefferies
- Delta Air shares slip despite strong outlook, Melius says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
